Valuation: Natera, Inc.

Capitalization 29.25B 24.94B 22.88B 21.65B 40.13B 2,799B 40.51B 272B 106B 1,328B 110B 107B 4,613B P/E ratio 2026 *
-123x
P/E ratio 2027 * -513x
Enterprise value 28.23B 24.08B 22.08B 20.9B 38.74B 2,702B 39.1B 263B 102B 1,282B 106B 104B 4,453B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 8.51x
Free-Float
96.86%
Yield 2026 *
-
Yield 2027 * -
1 day+2.55%
1 week-1.24%
Current month-0.95%
1 month+5.79%
3 months-1.74%
6 months-2.53%
Current year-10.86%
1 week 190.57
Extreme 190.57
221.56
1 month 189.53
Extreme 189.53
221.56
Current year 181
Extreme 181
256.36
1 year 131.81
Extreme 131.8106
256.36
3 years 36.9
Extreme 36.9
256.36
5 years 26.1
Extreme 26.1
256.36
10 years 7.35
Extreme 7.35
256.36
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/01/2020
Director of Finance/CFO 46 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Change 5d. change 1-year change 3-years change Capi.($)
+2.55%-1.24%+29.83%+299.63% 29.25B
-0.05%-0.16%-29.19%-47.85% 6.74B
+0.18%-5.12%-1.81%+107.56% 4.4B
-0.71%-0.66%+13.37%+56.87% 2.77B
-3.72%-0.55%-11.68%-64.03% 1.85B
-4.21%+4.60%+39.42%-23.14% 1.82B
-0.55%-0.79%+28.46%+2.60% 1.8B
+1.00%+8.53%+33.18%+244.58% 1.38B
-2.11%+8.26%+28.04%+62.25% 1.19B
-0.30%+14.43%-33.07%+473.57% 1.17B
Average -0.79%+2.54%+9.66%+111.20% 5.24B
Weighted average by Cap. +1.07%-0.49%+16.16%+188.66%

Financials

2026 *2027 *
Net sales 2.77B 2.36B 2.17B 2.05B 3.8B 265B 3.84B 25.81B 10.05B 126B 10.4B 10.18B 437B 3.27B 2.79B 2.56B 2.42B 4.49B 313B 4.54B 30.51B 11.88B 149B 12.29B 12.03B 517B
Net income -227M -193M -177M -168M -311M -21.7B -314M -2.11B -822M -10.29B -851M -833M -35.76B -52.01M -44.36M -40.69M -38.51M -71.37M -4.98B -72.06M -485M -189M -2.36B -195M -191M -8.21B
Net Debt -1.02B -868M -796M -753M -1.4B -97.39B -1.41B -9.48B -3.69B -46.2B -3.82B -3.74B -161B -1.29B -1.1B -1.01B -959M -1.78B -124B -1.79B -12.06B -4.7B -58.78B -4.86B -4.76B -204B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
12/05/26 204.21 $ +2.55% 1,566,969
11/05/26 199.14 $ +2.52% 2,041,865
08/05/26 194.24 $ -11.64% 3,925,677
07/05/26 219.82 $ +2.20% 2,765,926
06/05/26 215.09 $ +4.02% 2,136,392
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
204.21USD
Average target price
260.72USD
Spread / Average Target
+27.67%

Quarterly revenue - Rate of surprise